Get started
Cosmo Pharmaceuticals NVCosmo Pharmaceuticals NVCosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

No trades
See on Supercharts
Overview
Financials News Discussions Forecast Seasonals

C43 chart


Full chart

C43 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.16 B‬ EUR
Dividend yield (indicated)
2.98%
Price to earnings Ratio (TTM)
21.0
Basic EPS (TTM)
3.5 EUR
Net income (FY)
‪135.00 M‬ EUR
Revenue (FY)
‪270.31 M‬ EUR
Shares float
‪7.13 M‬
Beta (1Y)
0.94

Employees


Employees (FY)
321
Change (1Y)
0
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Cosmo Pharmaceuticals NV


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Giovanni di Napoli
Website
cosmopharma.com
Headquarters
Dublin
Founded
2016
ISIN
NL0011832936
FIGI
BBG00CWZRBW1
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Check out other big names from the same industry as C43.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

C43 news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Cosmo Pharmaceuticals NV stocks are traded under the ticker C43.
We've gathered analysts' opinions on Cosmo Pharmaceuticals NV future price: according to them, C43 price has a max estimate of 108.87 EUR and a min estimate of 87.51 EUR. Watch C43 chart and read a more detailed Cosmo Pharmaceuticals NV stock forecast: see what analysts think of Cosmo Pharmaceuticals NV and suggest that you do with its stocks.
C43 reached its all-time high on Nov 29, 2016 with the price of 173.5 EUR, and its all-time low was 35.0 EUR and was reached on Oct 27, 2023. View more price dynamics on C43 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Cosmo Pharmaceuticals NV financials in yearly and quarterly reports right on TradingView.
Cosmo Pharmaceuticals NV is going to release the next earnings report on Mar 25, 2026. Keep track of upcoming events with our Earnings Calendar.
C43 net income for the last half-year is ‪−2.02 M‬ EUR, while the previous report showed ‪57.47 M‬ EUR of net income which accounts for −103.52% change. Track more Cosmo Pharmaceuticals NV financial stats to get the full picture.
Yes, C43 dividends are paid annually. The last dividend per share was 2.05 EUR. As of today, Dividend Yield (TTM)% is 2.98%. Tracking Cosmo Pharmaceuticals NV dividends might help you take more informed decisions.
As of Sep 4, 2025, the company has 321 employees. See our rating of the largest employees — is Cosmo Pharmaceuticals NV on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cosmo Pharmaceuticals NV EBITDA is ‪65.06 M‬ EUR, and current EBITDA margin is 59.04%. See more stats in Cosmo Pharmaceuticals NV financial statements.
Like other stocks, C43 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cosmo Pharmaceuticals NV stock right from TradingView charts — choose your broker and connect to your account.